

# State and Federal Policy Updates

February 2018



## UNDER THE COLORADO STATE DOME

With nearly 50 days left of the legislative session we have already seen a high volume of bills that impact our industry - and continue

to expect movement and introduction of additional legislation. Throughout the session, CBSA works to advance legislation that improves the business, workforce and industry growth strategies in the State as well as addresses bills which stand to have a negative impact on the industry. Of the bills introduced to date this session:

### CBSA SUPPORTS

- [HB18-1135](#): Extend Advanced Industry Export Acceleration Program
- [HB18-1185](#): Market Sourcing for Business Income Tax Apportionment
- [SB18-022](#): Clinical Practice For Opioid Prescribing
- [SB18-042](#): Concerning the creation of the agricultural workforce development program

### CBSA OPPOSES

- [HB18 – 1009](#): Diabetes Drug Pricing Transparency Act 2018
- [HB18-1260](#): Prescription Drug Price Transparency
- [SB18-023](#): Promote Off-label Use Pharmaceutical Products
- [SB18 – 080](#): Wholesale Canadian Drug Importation Program

### CBSA NEUTRAL

- [HB18-1128](#): Protections for Consumer Data Privacy
- [SB18-152](#): Prohibit Price Gouging on Prescription Drugs
- [HB18-1179](#): Prohibit Price Gouging on Prescription Drugs



**Jennifer Jones**  
CBSA Vice President



### GET INVOLVED

To learn more about these bills click [here](#) and to view CBSA's state policy priorities communication collateral click [here](#). If you'd like to discuss your concerns, perspective and position on these bills; or get engaged on any state or federal policy issues please contact CBSA vice president, [Jennifer Jones](#).

This month CBSA hosted a successful CBSA Day at the Capitol. Lieutenant Governor Donna Lynne started the event with an address on her top priorities, outlook on the opioid and substance abuse task force and the future of healthcare in our state. We also heard from legislators on what matters most to them and their communities, as well as learning why advocacy is so important to our industry. The day was capped with our life science showcase, an excellent opportunity for our member companies to interact directly with policymakers. Read more about the day [here](#), view the press release [here](#) and to check out the full photo album from the day on our [Facebook page](#).

# State and Federal Policy Updates

February 2018



## TRUE TRANSPARENCY

This month we launched a digital advocacy campaign focusing on educating legislators, patients, and the business community on the drivers contributing to the cost of prescription drugs, 'true transparency.' True transparency means:

- Working together to provide patients access to affordable medicines
- Addressing the health care system as a whole
- Considering every player in the health care system to make meaningful changes for patients and their families

Over the next several weeks be sure follow CBSA on social media to view, like, and share our true transparency posts on [Facebook](#), [Twitter](#) and [LinkedIn](#). [Click here](#) to learn more about true transparency and to examine the cost of prescription drugs view CBSA's fact sheet.

## BIPARTISAN BUDGET ACT OF 2018

This month the President signed into law, the Bipartisan Budget Act Of 2018, a two-year budget deal which increases federal spending for defense as well as key domestic priorities, including many health programs. You can learn more about this Act in the recent [CBSA policy blog](#). In this deal we've seen some good and some surprises as it relates specifically to our industry.

The good

- Increased NIH funding
- Repealing IPAB
- Extended funding for CHIP for an additional 4 years

One of the surprises in the Act was a provision that increases discounts that pharmaceutical companies must give seniors enrolled in the Medicare Part D drug plans, by making the "doughnut hole" smaller.

We've reached out to our CO Delegation to express appreciation for the package including IPAB repeal, increased funding for the NIH and the CHIP extension. At the same time, we've voiced our concerns related to the proposed changes to the Medicare Part D program.

## ADVAMED FLY-IN

This month CBSA vice president Jennifer Jones and CBSA Board Member, policy committee co-chair, Dan Wittenberg, were in Washington, D.C. as part of the AdvaMed SMTA Fly In. This event brings medical technology representatives from across the country together for two days of legislative briefings and advocacy. There is a lot happening in the field, and we want to make sure Washington continues to promote the success of our Colorado companies. In addition to advocating for [CBSA Federal Policy](#) priorities, we also thanked our elected officials for their leadership and hard work for the recent suspension of the medical device excise tax and discussed what [we'd like to work towards](#) in the future in terms of a permanent repeal.



CBSA V.P. Jennifer Jones, Rep. Mike Coffman, CBSA Board Member Dan Wittenberg, and Zimmer Biomet Manager of Government Affairs Cate Thorin

On February 12, the Trump administration released the President's Budget outlining spending priorities for FY 2019. The proposal outlines recommended changes by the President to federal government spending. The recommendations specifically cover discretionary spending, not mandatory. Discretionary spending limits addressed in the proposal are set by congressional budget resolutions and it is typical that congress will make changes to the president's proposal. To read more about what is included in the budget [click here](#).

CBSA will work with our national organizations, the Colorado Delegation and members to ensure we advocate on the behalf of our industry.